PL2215117T5 - Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej - Google Patents

Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej

Info

Publication number: PL2215117T5
Authority: PL; Poland
Prior art keywords: cation exchange; exchange chromatography; antibody purification; antibody; purification
Prior art date: 2007-10-30

Application number

PL08844379T

Other languages

English (en)

Other versions

PL2215117T3 (pl

Inventor

Benedicte Andree Lebreton

Deborah Ann O'connor

Aurelia Safta

Mandakini Sharma

Original Assignee

Genentech, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-30

Filing date

2008-10-29

Publication date

2018-06-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2215117(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-29 Application filed by Genentech, Inc. filed Critical Genentech, Inc.

2015-06-30 Publication of PL2215117T3 publication Critical patent/PL2215117T3/pl

2018-06-29 Publication of PL2215117T5 publication Critical patent/PL2215117T5/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Analytical Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

PL08844379T 2007-10-30 2008-10-29 Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej PL2215117T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98382507P	2007-10-30	2007-10-30
PCT/US2008/081516 WO2009058812A1 (en)	2007-10-30	2008-10-29	Antibody purification by cation exchange chromatography
EP08844379.1A EP2215117B2 (en)	2007-10-30	2008-10-29	Antibody purification by cation exchange chromatography

Publications (2)

Publication Number	Publication Date
PL2215117T3 PL2215117T3 (pl)	2015-06-30
PL2215117T5 true PL2215117T5 (pl)	2018-06-29

Family

ID=40262967

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL12189190T PL2565206T3 (pl)	2007-10-30	2008-10-29	Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
PL08844379T PL2215117T5 (pl)	2007-10-30	2008-10-29	Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
PL14189095T PL2840090T3 (pl)	2007-10-30	2008-10-29	Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL12189190T PL2565206T3 (pl)	2007-10-30	2008-10-29	Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL14189095T PL2840090T3 (pl)	2007-10-30	2008-10-29	Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej

Country Status (32)

Country	Link
US (3)	US20090148435A1 (pl)
EP (4)	EP2215117B2 (pl)
JP (5)	JP5237382B2 (pl)
KR (3)	KR20140015166A (pl)
CN (3)	CN101889025B (pl)
AR (2)	AR069097A1 (pl)
AU (1)	AU2008318865B2 (pl)
BR (1)	BRPI0817182A2 (pl)
CA (1)	CA2703279C (pl)
CL (1)	CL2008003218A1 (pl)
CO (1)	CO6280422A2 (pl)
CY (1)	CY1116129T1 (pl)
DK (3)	DK2215117T4 (pl)
ES (3)	ES2533266T5 (pl)
HK (1)	HK1221234A1 (pl)
HR (2)	HRP20150282T4 (pl)
HU (3)	HUE027668T2 (pl)
IL (4)	IL205310A0 (pl)
ME (1)	ME02101B (pl)
MX (1)	MX2010004740A (pl)
NZ (1)	NZ584839A (pl)
PE (1)	PE20091434A1 (pl)
PH (1)	PH12013501128A1 (pl)
PL (3)	PL2565206T3 (pl)
PT (1)	PT2215117E (pl)
RS (1)	RS53850B2 (pl)
RU (1)	RU2498991C2 (pl)
SG (2)	SG10201401690XA (pl)
SI (3)	SI2840090T1 (pl)
TW (2)	TWI554517B (pl)
WO (1)	WO2009058812A1 (pl)
ZA (2)	ZA201002850B (pl)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR201809892T4 (tr)	2003-11-05	2018-07-23	Roche Glycart Ag	Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CN102580084B (zh) *	2005-01-21	2016-11-23	健泰科生物技术公司	Her抗体的固定剂量给药
MX2007009889A (es)	2005-02-23	2007-09-07	Genentech Inc	Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
CN103276033A (zh)	2006-09-13	2013-09-04	雅培制药有限公司	细胞培养改良
ES2477497T3 (es)	2007-03-02	2014-07-17	Genentech, Inc.	Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
US20090148435A1 (en)	2007-10-30	2009-06-11	Genentech, Inc.	Antibody purification by cation exchange chromatography
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
TW201438738A (zh)	2008-09-16	2014-10-16	Genentech Inc	治療進展型多發性硬化症之方法
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
CN104974251A (zh) *	2008-10-20	2015-10-14	Abbvie公司	在抗体纯化过程中的病毒灭活
CN105111309A (zh)	2008-10-20	2015-12-02	Abbvie公司	使用a蛋白亲和层析分离和纯化抗体
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2480561B1 (en) *	2009-09-23	2016-07-13	E. R. Squibb & Sons, L.L.C.	Cation exchange chromatography
CN103237810A (zh) *	2010-02-23	2013-08-07	霍夫曼-拉罗奇有限公司	用于治疗卵巢癌的抗血管发生疗法
TWI426920B (zh)	2010-03-26	2014-02-21	Hoffmann La Roche	雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN103097416B (zh) *	2010-03-30	2015-09-09	詹森生物科技公司	人源化il-25抗体
HUE049725T2 (hu)	2010-05-14	2020-10-28	Univ Oregon Health & Science	Hepatitisz B vírusból izolált heterológ antigént kódoló rekombináns HCMV és RhCMV vektorok és alkalmazásuk
EP4492053A3 (en)	2010-05-25	2025-03-19	F. Hoffmann-La Roche AG	Methods of purifying polypeptides
GB201012603D0 (en)	2010-07-27	2010-09-08	Ucb Pharma Sa	Protein purification
EP2655412B1 (en) *	2010-12-21	2018-01-17	F. Hoffmann-La Roche AG	Isoform enriched antibody preparation and method for obtaining it
KR102058254B1 (ko) *	2011-03-29	2019-12-20	글락소스미스클라인 엘엘씨	단백질 정제용 완충제 시스템
WO2012160530A1 (en) *	2011-05-26	2012-11-29	Dr. Reddy's Laboratories Limited	Purification of antibodies
PL2691530T3 (pl)	2011-06-10	2019-02-28	Oregon Health & Science University	Glikoproteiny i rekombinowane wektory CMV
WO2013054250A1 (en) *	2011-10-10	2013-04-18	Dr Reddy's Laboratories Limited	Purification method
WO2013055874A2 (en)	2011-10-14	2013-04-18	Genentech, Inc.	Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
RU2478646C1 (ru) *	2011-11-28	2013-04-10	Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН)	Способ получения высокоаффинных поликлональных антител
HRP20181846T1 (hr)	2011-12-22	2018-12-28	Genentech, Inc.	Kromatografija membranom za ionsku izmjenu
PE20150361A1 (es)	2012-07-13	2015-03-14	Roche Glycart Ag	Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
WO2014034644A1 (ja) *	2012-08-27	2014-03-06	旭化成メディカル株式会社	温度応答性クロマトグラフィーによる抗体の精製方法
CN103217499B (zh) *	2013-01-15	2015-12-02	珠海市丽珠单抗生物技术有限公司	一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法
IL274646B (en)	2013-03-08	2022-09-01	Genzyme Corp	Integrated continuous production of medicinal substances from medical protein
UY35517A (es)	2013-04-04	2014-10-31	Mabxience S A	Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína
AR095863A1 (es)	2013-04-16	2015-11-18	Genentech Inc	Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
US10351592B2 (en)	2013-10-30	2019-07-16	Celltrion, Inc.	Method for separating antibody isoforms using cation exchange chromatography
CN104628846B (zh) *	2013-11-06	2019-12-06	三生国健药业（上海）股份有限公司	重组蛋白质的纯化方法
MX383206B (es) *	2013-11-25	2025-03-13	Seagen Inc	Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.
TWI709569B (zh)	2014-01-17	2020-11-11	美商健臻公司	無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh)	2014-01-17	2020-11-11	美商健臻公司	無菌層析法及製法
WO2015120056A1 (en)	2014-02-04	2015-08-13	Biogen Ma Inc.	Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3674310A1 (en)	2014-03-10	2020-07-01	Richter Gedeon Nyrt.	Immunoglobulin purification using pre-cleaning steps
CN105017418B (zh) *	2014-03-27	2021-02-23	上海药明康德新药开发有限公司	单克隆抗体纯化工艺方法
WO2015164665A1 (en)	2014-04-25	2015-10-29	Genentech, Inc.	Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
AU2015289560B2 (en)	2014-07-16	2018-09-27	Oregon Health & Science University	Human cytomegalovirus comprising exogenous antigens
CN105315369B (zh) *	2014-07-25	2020-03-13	山东博安生物技术有限公司	利用阳离子交换层析纯化蛋白质
AU2016233557B2 (en) *	2015-03-13	2021-06-24	Bristol-Myers Squibb Company	Use of alkaline washes during chromatography to remove impurities
CN107614015A (zh)	2015-05-30	2018-01-19	豪夫迈·罗氏有限公司	治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
KR101657690B1 (ko) *	2015-06-05	2016-09-19	주식회사 녹십자홀딩스	혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법
WO2017087280A1 (en)	2015-11-16	2017-05-26	Genentech, Inc.	Methods of treating her2-positive cancer
CN108474003A (zh)	2015-11-20	2018-08-31	俄勒冈健康与科学大学	包含微小rna识别元件的cmv载体
GB201600512D0 (en)	2016-01-12	2016-02-24	Univ York	Recombinant protein production
IL262207B1 (en)	2016-04-15	2025-09-01	Univ Pennsylvania	Compositions for treatment of wet age-related macular degeneration
US10654922B2 (en) *	2016-05-13	2020-05-19	Askgene Pharma Inc.	Angiopoietin 2, VEGF dual antagonists
CN109415427A (zh) *	2016-07-15	2019-03-01	豪夫迈·罗氏有限公司	用于纯化聚乙二醇化的促红细胞生成素的方法
CN106222222B (zh) *	2016-08-08	2019-10-29	湖北医药学院	一种重组人白血病抑制因子的制备方法
WO2018045587A1 (zh) *	2016-09-12	2018-03-15	广东东阳光药业有限公司	一种抗vegf类单克隆抗体的纯化方法
CN106380519B (zh) *	2016-10-17	2019-11-01	深圳万乐药业有限公司	一种单克隆抗体的纯化方法
TN2019000124A1 (en)	2016-10-18	2020-10-05	Univ Oregon Health & Science	Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
EP3532498A1 (en) *	2016-10-31	2019-09-04	Hexal AG	Antibody preparation
CN110099926A (zh)	2016-12-28	2019-08-06	豪夫迈·罗氏有限公司	晚期her2表达性癌症的治疗
KR20210134432A (ko)	2017-01-17	2021-11-09	제넨테크, 인크.	피하 her 2 항체 제형
LT3589661T (lt)	2017-03-02	2024-02-12	Genentech, Inc.	Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas
BE1025090B1 (fr) *	2017-03-30	2018-10-29	Univercells Sa	Procede et kit de purification de proteines
WO2018190677A2 (en) *	2017-04-14	2018-10-18	Cj Healthcare Corporation	Method for purifying analogous antibody using cation-exchange chromatography
JP2020517273A (ja)	2017-04-24	2020-06-18	ジェネンテック，インコーポレイテッド	膜貫通ドメインまたは膜近傍ドメインにおけるＥｒｂＢ２／Ｈｅｒ２突然変異
JP2020525445A (ja) *	2017-06-21	2020-08-27	セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	カチオン交換クロマトグラフィーの洗浄緩衝液
WO2019060718A1 (en) *	2017-09-22	2019-03-28	Immunogen, Inc.	SEPARATION OF LIGHT TRIPLE CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY
CN110272491B (zh) *	2018-03-13	2023-01-24	江苏恒瑞医药股份有限公司	一种抗pd-1抗体的纯化工艺
WO2019191416A1 (en) *	2018-03-29	2019-10-03	Bristol-Myers Squibb Company	Methods of purifying monomeric monoclonal antibodies
US11612885B2 (en) *	2018-05-08	2023-03-28	Waters Technologies Corporation	Methods, compositions and kits useful for pH gradient cation exchange chromatography
CN109053895B (zh)	2018-08-30	2020-06-09	中山康方生物医药有限公司	抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
EP3843869A1 (en)	2018-08-31	2021-07-07	Genzyme Corporation	Sterile chromatography resin and use thereof in manufacturing processes
EP3643322A1 (en) *	2018-10-26	2020-04-29	Mabion SA	Low aggregate anti cd20 ligand formulation
CN109320611B (zh) *	2018-10-31	2022-06-03	鼎康(武汉)生物医药有限公司	一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN112206327A (zh) *	2019-07-12	2021-01-12	上海药明生物技术有限公司	一种抗体偶联药物的制备及其高通量筛选方法
US20220396598A1 (en) *	2019-10-14	2022-12-15	Pierce Biotechnology, Inc.	Peptide purification formulations and methods
CA3160208A1 (en) *	2019-11-07	2021-05-14	Amgen Inc.	High salt washes during cation exchange chromatography to remove product-realated impurities
BR112022010069A2 (pt) *	2019-11-25	2022-09-06	Akeso Biopharma Inc	Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica
KR102153258B1 (ko) *	2020-02-21	2020-09-07	프레스티지바이오로직스 주식회사	베바시주맙 정제의 최적화된 방법
BR112022019042A2 (pt) *	2020-03-25	2022-11-01	Jiangsu Hengrui Pharmaceuticals Co Ltd	Método de preparação para conjugado anticorpo-fármaco
EP4171748A1 (en)	2020-06-29	2023-05-03	Genentech, Inc.	Pertuzumab plus trastuzumab fixed dose combination
US11416468B2 (en) *	2020-07-21	2022-08-16	International Business Machines Corporation	Active-active system index management
CN114591438B (zh) *	2022-04-25	2023-12-05	达石药业(广东)有限公司	一种采用阳离子交换层析法纯化双特异性抗体的方法
CN120112310A (zh)	2022-10-26	2025-06-06	日本医事物理股份有限公司	放射性药物组合物的制造方法
CN115850493B (zh) *	2022-11-08	2024-03-12	江苏耀海生物制药有限公司	一种二价纳米抗体Cablivi的分离纯化方法
CN117756878A (zh) *	2023-12-26	2024-03-26	康日百奥生物科技(苏州)有限公司	抗体层析分离方法及应用
WO2025193804A1 (en) *	2024-03-12	2025-09-18	Massachusetts Eye And Ear Infirmary	Methods and materials for treating ocular neovascular diseases
WO2025232755A1 (zh) *	2024-05-07	2025-11-13	南京蓬勃生物科技有限公司	一种使用阳离子交换层析纯化目标蛋白的方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4515893A (en)	1979-04-26	1985-05-07	Ortho Pharmaceutical Corporation	Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
GB2070818A (en)	1980-02-04	1981-09-09	Philips Electronic Associated	Regulated power supply for an image intensifier
WO1984002129A1 (fr)	1982-11-22	1984-06-07	Takeda Chemical Industries Ltd	Proteine de l'interferon immun humain et son procede de preparation
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DD266710A3 (de)	1983-06-06	1989-04-12	Ve Forschungszentrum Biotechnologie	Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
US4753894A (en)	1984-02-08	1988-06-28	Cetus Corporation	Monoclonal anti-human breast cancer antibodies
US5169774A (en)	1984-02-08	1992-12-08	Cetus Oncology Corporation	Monoclonal anti-human breast cancer antibodies
WO1986002068A1 (fr) *	1984-09-26	1986-04-10	Takeda Chemical Industries, Ltd.	Separation mutuelle de proteines
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US5196323A (en)	1985-04-27	1993-03-23	Boehringer Ingelheim International Gmbh	Process for preparing and purifying alpha-interferon
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US5525338A (en) *	1992-08-21	1996-06-11	Immunomedics, Inc.	Detection and therapy of lesions with biotin/avidin conjugates
US5091178A (en)	1986-02-21	1992-02-25	Oncogen	Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
CA1283072C (en)	1986-12-01	1991-04-16	Timothy Durance	Process for the isolation and separation of lysozyme and avidin from eggwhite
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5451662A (en)	1987-10-23	1995-09-19	Schering Corporation	Method of purifying protein
US5118796A (en)	1987-12-09	1992-06-02	Centocor, Incorporated	Efficient large-scale purification of immunoglobulins and derivatives
US5091313A (en)	1988-08-05	1992-02-25	Tanox Biosystems, Inc.	Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en)	1988-01-12	1998-02-24	Genentech, Inc.	In vivo tumor detection assay
JP3040121B2 (ja) *	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IT1219874B (it)	1988-03-18	1990-05-24	Fidia Farmaceutici	Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5115101A (en)	1988-06-08	1992-05-19	Miles Inc.	Removal of protein A from antibody preparations
EP0420937B1 (en)	1988-06-21	1994-11-09	Genentech, Inc.	Therapeutic compositions for the treatment of myocardial infarction
EP0435911B1 (en)	1988-09-23	1996-03-13	Cetus Oncology Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP0402226A1 (en)	1989-06-06	1990-12-12	Institut National De La Recherche Agronomique	Transformation vectors for yeast yarrowia
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5112951A (en) *	1989-07-28	1992-05-12	Hybritech Incorporated	Separation of anti-metal chelate antibodies
US5110913A (en)	1990-05-25	1992-05-05	Miles Inc.	Antibody purification method
EP0467466A1 (en) *	1990-07-16	1992-01-22	Eastman Kodak Company	Method for the purification of immunoreactive labeled thyroxine conjugates
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
EP1260521B1 (en)	1991-08-14	2007-11-21	Genentech Inc.	Immunoglobulin variants for specific Fc epsilon receptors
JP3951062B2 (ja)	1991-09-19	2007-08-01	ジェネンテック・インコーポレーテッド	少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
EP1136556B1 (en)	1991-11-25	2005-06-08	Enzon, Inc.	Method of producing multivalent antigen-binding proteins
JPH05202098A (ja)	1992-01-29	1993-08-10	Snow Brand Milk Prod Co Ltd	乳質原料から生理活性物質の製造法
EP1997894B1 (en)	1992-02-06	2011-03-30	Novartis Vaccines and Diagnostics, Inc.	Biosynthetic binding protein for cancer marker
US5279823A (en)	1992-06-08	1994-01-18	Genentech, Inc.	Purified forms of DNASE
ATE161192T1 (de)	1992-08-21	1998-01-15	Genentech Inc	Verfahren zur behandlung einer durch lfa-1 vermittelten störung
PT752248E (pt)	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
ES2108566T3 (es)	1993-12-10	1997-12-16	Genentech Inc	Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
ATE164079T1 (de)	1994-01-18	1998-04-15	Genentech Inc	Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
US5707622A (en)	1994-03-03	1998-01-13	Genentech, Inc.	Methods for treating ulcerative colitis
US5534615A (en)	1994-04-25	1996-07-09	Genentech, Inc.	Cardiac hypertrophy factor and uses therefor
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5714583A (en)	1995-06-07	1998-02-03	Genetics Institute, Inc.	Factor IX purification methods
WO1996040210A1 (en)	1995-06-07	1996-12-19	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth of tumors
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
EP1297847A3 (en)	1996-01-23	2003-05-07	Genentech, Inc.	Anti-CD18 antibodies in stroke
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP0942930B1 (en)	1996-11-15	2007-08-29	Genentech, Inc.	Purification of neurotrophins
ATE267257T1 (de)	1996-11-27	2004-06-15	Genentech Inc	Humanisierte anti-koerper gegen cd11a
ES2335365T3 (es) *	1996-11-27	2010-03-25	Genentech, Inc.	Purificacion por afinidad de polipeptido en una matriz de proteina a.
ES2361267T3 (es)	1997-04-07	2011-06-15	Genentech Inc.	Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
ES2273415T3 (es)	1997-04-07	2007-05-01	Genentech, Inc.	Anticuerpos anti-vegf.
ATE516354T1 (de)	1997-05-15	2011-07-15	Genentech Inc	Apo-2-rezeptor
US5994511A (en)	1997-07-02	1999-11-30	Genentech, Inc.	Anti-IgE antibodies and methods of improving polypeptides
KR100960211B1 (ko)	1998-05-06	2010-05-27	제넨테크, 인크.	이온 교환 크로마토그래피에 의한 단백질 정제 방법
IL139609A (en)	1998-06-01	2006-06-11	Genentech Inc	Separation of polypeptides monomers
DK1084147T3 (da)	1998-06-09	2004-10-25	Statens Seruminstitut	Fremgangsmåde til fremstilling af immunglobuliner til administration og andre immunglobulinprodukter
PL203326B1 (pl)	1999-06-25	2009-09-30	Genentech Inc	Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
CA2387108A1 (en)	1999-10-29	2001-06-07	Genentech, Inc.	Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US6417355B1 (en)	2001-04-11	2002-07-09	The United States Of America As Represented By The Secretary Of The Navy	Geminal-dinitro-1-5 diazocine derivatives
GB0113179D0 (en) *	2001-05-31	2001-07-25	Novartis Ag	Organic compounds
US7321026B2 (en)	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
US6770027B2 (en) *	2001-10-05	2004-08-03	Scimed Life Systems, Inc.	Robotic endoscope with wireless interface
EP1507793A4 (en)	2001-10-17	2006-02-01	Human Genome Sciences Inc	NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
KR101033196B1 (ko)	2002-02-14	2011-05-09	이뮤노메딕스, 인코오포레이티드	항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
EP1551875A4 (en) *	2002-06-21	2006-06-28	Biogen Idec Inc	TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
JP5303092B2 (ja) *	2002-09-11	2013-10-02	ジェネンテック，インコーポレイテッド	タンパク質精製
PT1558648E (pt)	2002-10-17	2012-04-23	Genmab As	Anticorpos monoclonais humanos contra cd20
WO2004054615A1 (en)	2002-12-13	2004-07-01	Mitra Medical Technology Ab	Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
AR042485A1 (es)	2002-12-16	2005-06-22	Genentech Inc	Anticuerpo humanizado que se une al cd20 humano
NZ554885A (en)	2002-12-31	2009-07-31	Altus Pharmaceuticals Inc	Complexes of hgh crystals and protamine polymers
US20060257972A1 (en) *	2003-03-31	2006-11-16	Takashi Ishihara	Purification of human monoclonal antibody and human polyclonal antibody
KR101412271B1 (ko)	2003-05-09	2014-06-25	듀크 유니버시티	Ｃｄ２０-특이적 항체 및 이를 이용한 방법
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
WO2005014618A2 (en)	2003-08-08	2005-02-17	Immunomedics, Inc.	Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en)	2003-08-14	2012-04-03	Merck Patent Gmbh	CD20-binding polypeptide compositions and methods
KR100524074B1 (ko)	2003-10-01	2005-10-26	삼성전자주식회사	베젤 구조를 가지는 전자기기
TW200533357A (en) *	2004-01-08	2005-10-16	Millennium Pharm Inc	2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
CN101022829A (zh) *	2004-04-16	2007-08-22	健泰科生物技术公司	用抗cd20抗体治疗多软骨炎和多发性单神经炎
EP1742660A2 (en) †	2004-04-16	2007-01-17	Genentech, Inc.	Treatment of disorders
JP2008525041A (ja) *	2004-12-22	2008-07-17	ジェネンテック・インコーポレーテッド	可溶性多膜貫通型タンパク質の産生方法
MX2007011129A (es) *	2005-03-11	2007-11-06	Wyeth Corp	Un metodo de cromatografia de particion debil.
CA2611815A1 (en) *	2005-06-17	2006-12-28	Elan Pharma International Limited	Methods of purifying anti a beta antibodies
WO2007028154A2 (en) *	2005-09-02	2007-03-08	Northwestern University	Encapsulated arsenic drugs
CN101437839A (zh) *	2006-03-20	2009-05-20	米德列斯公司	蛋白质纯化
NZ611859A (en) *	2006-04-05	2014-12-24	Abbvie Biotechnology Ltd	Antibody purification
JP2010501623A (ja) *	2006-08-28	2010-01-21	アレストレーディングソシエテアノニム	Ｆｃ含有タンパク質の精製法
US8620738B2 (en)	2006-08-31	2013-12-31	Visa U.S.A. Inc	Loyalty program incentive determination
WO2008121615A2 (en) *	2007-03-30	2008-10-09	Medimmune, Inc.	Antibody formulation
US20090148435A1 (en) *	2007-10-30	2009-06-11	Genentech, Inc.	Antibody purification by cation exchange chromatography
JP5731726B1 (ja)	2014-06-26	2015-06-10	楽天株式会社	情報処理装置、情報処理方法及び情報処理プログラム

2008
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Ceased
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active Active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en not_active Ceased
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Ceased
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
2014
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
2015
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown

Also Published As

Publication number	Publication date
JP5237382B2 (ja)	2013-07-17
ES2533266T3 (es)	2015-04-08
DK2215117T4 (en)	2018-04-09
CN105315323A (zh)	2016-02-10
HUE037409T2 (hu)	2018-08-28
US20090148435A1 (en)	2009-06-11
AR111171A2 (es)	2019-06-12
SI2565206T1 (sl)	2016-07-29
TWI554517B (zh)	2016-10-21
CN103554215A (zh)	2014-02-05
US9896478B2 (en)	2018-02-20
AR069097A1 (es)	2009-12-30
KR20100086015A (ko)	2010-07-29
CN101889025B (zh)	2013-11-13
EP2840090A1 (en)	2015-02-25
ES2533266T5 (es)	2018-04-18
JP2015145371A (ja)	2015-08-13
EP2840090B1 (en)	2018-02-21
PE20091434A1 (es)	2009-10-17
HRP20180943T1 (hr)	2018-08-10
TW200927289A (en)	2009-07-01
IL234902A0 (en)	2014-11-30
CN103554215B (zh)	2016-06-15
SG10201401690XA (en)	2014-06-27
RS53850B1 (sr)	2015-08-31
TWI448330B (zh)	2014-08-11
ZA201002850B (en)	2011-07-27
CA2703279C (en)	2014-04-22
CO6280422A2 (es)	2011-05-20
DK2840090T3 (en)	2018-04-23
EP2215117B1 (en)	2014-12-31
IL239495A0 (en)	2015-08-31
HRP20150282T4 (hr)	2018-08-10
US20150056196A1 (en)	2015-02-26
AU2008318865B2 (en)	2012-06-28
IL234901A0 (en)	2014-11-30
HUE027668T2 (en)	2016-11-28
RS53850B2 (sr)	2018-07-31
EP2215117A1 (en)	2010-08-11
HK1206753A1 (en)	2016-01-15
NZ584839A (en)	2012-07-27
CY1116129T1 (el)	2017-02-08
JP5885864B2 (ja)	2016-03-16
ES2666170T3 (es)	2018-05-03
MX2010004740A (es)	2010-05-27
TW201512216A (zh)	2015-04-01
BRPI0817182A2 (pt)	2015-03-17
RU2498991C2 (ru)	2013-11-20
DK2215117T3 (en)	2015-03-02
SG175597A1 (en)	2011-11-28
JP2015155406A (ja)	2015-08-27
DK2565206T3 (en)	2016-06-06
HK1221234A1 (zh)	2017-05-26
EP3441402A1 (en)	2019-02-13
ES2572958T3 (es)	2016-06-03
JP2017019790A (ja)	2017-01-26
SI2215117T1 (sl)	2015-03-31
HK1143821A1 (en)	2011-01-14
RU2010121816A (ru)	2011-12-10
EP2215117B2 (en)	2018-01-10
EP2565206A3 (en)	2013-11-06
SI2215117T2 (en)	2018-04-30
EP2565206B1 (en)	2016-03-30
KR20150008503A (ko)	2015-01-22
PL2565206T3 (pl)	2017-08-31
ME02101B (me)	2015-10-20
PH12013501128A1 (en)	2015-12-02
ZA201102169B (en)	2012-12-27
HK1182401A1 (en)	2013-11-29
CL2008003218A1 (es)	2009-03-06
AU2008318865A1 (en)	2009-05-07
KR20140015166A (ko)	2014-02-06
HRP20150282T1 (hr)	2015-06-19
JP2013173747A (ja)	2013-09-05
EP2565206A2 (en)	2013-03-06
IL205310A0 (en)	2010-12-30
CN101889025A (zh)	2010-11-17
PL2840090T3 (pl)	2018-07-31
WO2009058812A1 (en)	2009-05-07
US20180118781A1 (en)	2018-05-03
HUE024877T2 (en)	2016-02-29
CA2703279A1 (en)	2009-05-07
JP2011502161A (ja)	2011-01-20
KR101241486B1 (ko)	2013-03-15
PL2215117T3 (pl)	2015-06-30
PT2215117E (pt)	2015-04-01
IL239495B (en)	2019-09-26
SI2840090T1 (en)	2018-05-31

Publication	Publication Date	Title
IL239495B (en)	2019-09-26	Antibody purification using cation exchange chromatography
IL194236A0 (en)	2011-08-01	Antibody purification
IL201388A0 (en)	2010-05-31	Immunoglobulin purification
IL225720A0 (en)	2013-06-27	Antibody purification in one ion exchange chromatography unit
ZA200906345B (en)	2010-11-24	Anti-sclerostin antibodies
PL2195026T3 (pl)	2014-05-30	Przeciwciała przeciw sklerostynie
EP2519536A4 (en)	2013-06-05	PROTEIN PURIFICATION BY ION EXCHANGE
HRP20182146T1 (hr)	2019-02-08	Formulacije protutijela natalizumab
IL204835A0 (en)	2010-11-30	Humanized antibody
EP2125890A4 (en)	2010-04-07	ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
PL1985871T3 (pl)	2017-09-29	Układ do mocowania dwóch elementów na sobie
PT2220107T (pt)	2017-02-08	Polipéptidos de afinidade dupla para purificação
IL212646A0 (en)	2011-07-31	Immunoglobulin purification
PL2748179T3 (pl)	2022-04-11	Oczyszczanie białka metodą anionowej chromatografii jonowymiennej
IL229763A0 (en)	2014-01-30	Purification of antibodies in single chromatography
GB0724148D0 (en)	2008-01-23	Improvements relating to column chromatography
ZA201100565B (en)	2014-09-25	Antibody purification
IL211067A0 (en)	2011-04-28	Affinity purification by cohesin-dockerin interaction
GB0517651D0 (en)	2005-10-05	Alterations to pipe movement apparatus
GB0706965D0 (en)	2007-05-16	Humanized antibody
GB0706964D0 (en)	2007-05-16	Humanized antibody
GB0706963D0 (en)	2007-05-16	Humanized antibody
GB0707722D0 (en)	2007-05-30	Novel compounds A3